A federal securities class action has been filed against Inovio Pharmaceuticals Inc., alleging that the company and its executives violated federal securities laws by making false or misleading statements and failing to disclose issues related to the manufacturing of its CELLECTRA device. The complaint claims that these deficiencies made it unlikely for Inovio to submit its INO-3107 Biologics License Application to the FDA by the projected timeline and that the company lacked sufficient information to justify the application’s eligibility for accelerated approval or priority review. As a result, the regulatory and commercial prospects for INO-3107 were allegedly overstated, leading to materially false and misleading public statements. Following the news, Inovio’s stock price dropped by 24.45 percent on December 29, 2025. Investors who acquired Inovio securities between October 10, 2023, and December 26, 2025, have until April 7, 2026, to seek appointment as lead plaintiff in the case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602140733PRIMZONEFULLFEED9654197) on February 14, 2026, and is solely responsible for the information contained therein.